Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 20

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 3
Chunk 20
---
 promise in identifying potential product candidates or indications yet fail to yield product candidates or indications for further clinical development.
 
We may not achieve our projected development goals in the time-frames we announce and expect.
 
We may set goals and make public statements regarding the timing of the accomplishment of objectives material to our success, such as the commencement, enrollment and anticipated completion of clinical trials, anticipated regulatory submission and approval dates and time of product launch. The actual timing of these events can vary dramatically due to factors such as delays or failures in any clinical trials, the uncertainties inherent in the regulatory approval process and delays in achieving manufacturing or marketing arrangements sufficient to commercialize any of our products or product candidates. There can be no assurance that we will make regulatory submissions or receive regulatory approvals as planned or that we will be able to adhere to our schedule for launching of any of our future product candidates, including avenanthramide products which are currently undergoing trials. If we fail to achieve one or more of these milestones as planned, the share price of our Common Shares may decline. 
 
Competition in our targeted markets is intense, and development by other companies our products non-competitive.
 
The cosmeceutical, nutraceutical and biopharmaceutical fields are highly competitive. New products developed by other companies in the industry could make our current and future products uncompetitive or significantly less competitive. Competitors are developing and testing products and technologies that would compete with any of our current and future products. Some of these competitive products may be more effective or have an entirely different approach or means of accomplishing the desired effect than our current and future products. We expect competition from our competitors to continue to increase over time. Many of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do.
 
We may not obtain adequate protection for our products through our intellectual property and trademark registrations.
 
We rely heavily on our proprietary information in developing and manufacturing our oat-based pipeline products, including oat-beta glucan, avenanthramides, beta glucan from PGX, and Macrilen™ (macimorelin). Our success depends, in large part, on our ability to protect our competitive position through patents, trade secrets, trademarks and other intellectual property rights. We have filed and are pursuing applications for patents and trademarks in many countries. Pending patent applications may not result in the issuance of patents, and we may not be able to obtain additional issued patents relating to our products.
 
The laws of some countries do not